soliris
Japan approves AstraZeneca’s Soliris for paediatric patients with gMG
August 24, 2023Medical Communications AstraZeneca, MHLW, Musculo-skeletal disorder, gMG, paediatric, soliris
AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris (eculizumab) for the extended use …
AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation
June 26, 2023Medical Communications AstraZeneca, CHMP, EMA, Immunology, soliris
UK-based biopharmaceutical company AstraZeneca has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
Apellis therapy outflanks Alexion’s Soliris in head-to-head paroxysmal nocturnal haemoglobinuria
January 8, 2020Research and Development Alexion, Appelis, pegcetacoplan, pharma, soliris
Apellis Pharmaceuticals has revealed new Phase 3 demonstrating that its targeted C3 inhibitor pegcetacoplan met its primary endpoint and outclassed …
Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder
August 28, 2019Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris
Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …
Alexion’s Soliris almost entirely eliminates relapses in rare neuromyelitis optica spectrum disorder
September 26, 2018Research and Development Alexion, neuromyelitis optica spectrum disorder, pharma, rare disease, soliris
Alexion has revealed new Phase 3 findings for Soliris (eculizumab), showing the drug met its primary endpoint in the treatment …
Alexion goes back to roots with Complement deal
June 11, 2018Manufacturing and Production, Sales and Marketing Alexion, biotech, drugs, pharma, pharmaceutical, soliris
Alexion has made a lot of money from investing in the science behind complement inhibitors – C5 inhibitor, Soliris, has …
Investigational Alexion drug proves non-inferior to Soliris in rare blood disease
April 27, 2018Medical Communications, Research and Development Alexion, paroxysmal nocturnal haemoglobinuria, pharma, soliris
Alexion has lifted the curtain on new data for its C5 complement inhibitor ALXN1210, demonstrating its non-inferiority to another of …
Alexion moves to bolster patent protection of Soliris
August 17, 2017Sales and Marketing Alexion, biotech, drugs, pharma, pharmaceutical, soliris
Soliris brought in net sales of $2.8 billion last year for Alexion, meaning it accounted for close to 90% of …
Alexion to challenge Canadian price of Soliris in court
September 28, 2015Sales and Marketing Alexion, Canada, Drug pricing, Patented Medicine Prices Review Board, eculizumab, soliris
Alexion Pharmaceuticals is taking the Canadian government to court for its attempt to lower the price of the rare disease …
Alexion plans big expansion in Ireland
May 12, 2015Manufacturing and Production, Sales and Marketing Alexion, Dublin, Ireland, soliris
Alexion Pharmaceuticals is significantly expanding its operations in Ireland by building the US firm’s first ever biologics manufacturing facility outside …
NICE approves world’s most expensive drug
January 28, 2015Sales and Marketing Alexion, Dillon, NHS, NICE, aHUS, eculizumab, hst, soliris
The world’s most expensive drug has been approved in final guidance from NICE, making it the first drug to pass …
NHS to get world’s most expensive drug
November 27, 2014Sales and Marketing Alexion, NICE, aHUS, beauchamp, blood, eculizumab, soliris
UK health watchdog NICE has recommended Alexion’s Soliris for patients with the rare disease atypical haemolytic uremic syndrome (aHUS). Soliris …
NHS needs to understand drug costs better, says ABPI
April 10, 2014Medical Communications, Research and Development, Sales and Marketing ABPI, AGNSS, Deepak Khanna, NICE, Stephen Whitehead, Tarceva, soliris
The UK healthcare system is at risk of failing to adopt new, personalised medicines and must be willing to pay …
Alexion ‘concerned’ over NICE draft
March 4, 2014Sales and Marketing NICE, aHUS, alexia, blood, eculizumab, soliris
Alexion Pharmaceuticals UK has expressed ‘concern’ that NICE has not yet allowed its rare disease treatment Soliris to be formally …
Roche ‘considers’ Alexion bid
July 16, 2013Research and Development, Sales and Marketing Alexion, Orphan, Roche, soliris
Speculation that Roche is considering a bid for rare disease specialist Alexion Pharmaceuticals has unleashed a flurry of comment – …
